Impact Analysis of Covid-19

The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.

Heparin, also known as unfractionated heparin (UFH), is a medication and naturally occurring glycosaminoglycan. Heparin acts as an anticoagulant and is used for conditions such as acute coronary syndrome, atrial fibrillation (AF), venous thromboembolism (VTE), cardiopulmonary bypass for heart surgery, Extracorporeal Membrane Oxygenation (ECMO) circuit for extracorporeal life support, hemofiltration, and indwelling central or peripheral venous catheters.

Statistics:

Europe heparin market is estimated to account for US$ 4,085.8 Mn in terms of value by the end of 2027.

Europe Heparin Market: Drivers

High prevalence of AF is expected to propel growth of Europe heparin market over the forecast period. For instance, according to Heart and Circulatory Disease Statistics 2019 Published by the British Heart Foundation (BHF) in collaboration with the Institute of Applied Health Research at the University of Birmingham, in April 2019, 185,423 men and 155,331 women were diagnosed with AF in England, Scotland, Wales, Northern Ireland and United Kingdom in 2017/18.

Moreover, R&D to expand the application of heparin is also expected to aid in growth of the market. For instance, in June 2020, researchers from Chungbuk National University, South Korea, reported that heparin-binding peptide has potential in treatment of rheumatic arthritis.   

Statistics:

Germany held dominant position in Europe heparin market in 2019, accounting for 28.3% share in terms of volume, followed by France and U.K., respectively

Figure 1: Europe Heparin Market Share (%) Value, By Region, 2019

Europe Heparin  | Coherent Market Insights

Europe Heparin Market: Restraints

Availability of alternative anticoagulants is expected to hinder growth of the market. Warfarin has traditionally been the key preferred drug for anticoagulant therapy globally. Moreover, the advent of new anticoagulants such as rivaroxaban, dabigatran, and apixaban is cannibalizing the market share of heparin.

Moreover, use of heparin may lead to elevation of serum aminotransferase levels, hyperkalemia, alopecia, and osteoporosis. Such side effects are also expected to limit growth of the market.

request-sample

Europe Heparin Market Report Coverage

Report Coverage Details
Base Year: 2019 Market Size in 2019: US$ 2,698.7 Mn
Historical Data for: 2016 to 2019 Forecast Period: 2020 to 2027
Forecast Period 2020 to 2027 CAGR: 6.1% 2027 Value Projection: US$ 4,085.8 Mn
Geographies covered:
  • Europe: Germany, U.K., France, Spain, Italy, Russia, Rest of Europe.
Segments covered:
  • By Product Type: Low Molecular Weight Heparin, Unfractionated Heparin, Ultra Low Molecular Weight Heparin.
  • By End User: Hospitals, Blood and Stem Cell Bank, Others (Laboratories, Acute Care Centers).
Companies covered:

Pfizer, Inc., Sagent Pharmaceuticals, Inc., B. Braun Melsungen AG, Baxter International Inc., GlaxoSmithKline plc, Bayer AG, Anselm Pharmaceuticals, Bristol-Myers Squibb Co., Dr. Reddy’s Laboratories Ltd., Fresenius SE & Co. KGaA, Leap Labchem Co., LEO Pharma A/S, Sanofi S.A., Syntex S.A., Teva Pharmaceutical Industries Ltd., United Biotech (P) Ltd, Amphastar Pharmaceuticals Inc., Abbott Laboratories, Aspen Pharmacare Holdings, Laboratorios Farmaceuticos ROVI SA, and Intrapharm Laboratories

Growth Drivers:
  • Increasing prevalence of venous thromboembolism
Restraints & Challenges:
  • Risk of heparin induced thrombocytopenia

Europe Heparin Market: Opportunities 

Use of sharp-catching label to prevent needlestick injuries is expected to offer lucrative growth opportunities for players in Europe heparin market. For instance, Heparin Sodium Injection USP prefilled syringes from B. Braun Medical Inc. have a needle-securing label, developed by Schreiner MediPharm, on medical packaging.

Moreover, R&D in the mechanism of heparin is also expected to aid in growth of the market. For instance, in May 2020, researchers from Martin Luther University Halle Wittenberg, Germany, reported examining the anti-inflammatory properties of surface coatings made of either hyaluronic acid or heparin in combination with chitosan prepared as multilayers through the layer-by-layer technique.  

Statistics:

Europe heparin market was valued at US$ 2,698.7 Mn in 2019 and is forecast to reach a value of US$ 4,085.8 Mn by 2027 at a CAGR of 6.1% between 2020 and 2027.

Figure 2: Europe Heparin Market Value (US$ Mn), 2016 – 2027

Europe Heparin  | Coherent Market Insights

Market Trends/Key Takeaways

Major players in the market witnessed significant sales growth. For instance, in first quarter of 2020, Laboratorios Farmaceuticos Rovi S A reported increase in sales of the heparin franchise (LMWH and other heparins) by 42% to around US$ 60 million.

Major players in the market are also focused on assessing the efficacy of heparin alternatives in the treatment of VTE. For instance, in December 2019, the Bristol-Myers Squibb-Pfizer alliance announced that Eliquis use was associated with lower rates of major bleeding, clinically-relevant non-major bleeding and recurrent VTE compared to LMWH for the treatment of VTE in patients with active cancer, at the American Society of Hematology Annual Meeting.

Global Europe Heparin Market: Competitive Landscape

Major players operating in Europe heparin market include, Pfizer, Inc., Sagent Pharmaceuticals, Inc., B. Braun Melsungen AG, Baxter International Inc., GlaxoSmithKline plc, Bayer AG, Anselm Pharmaceuticals, Bristol-Myers Squibb Co., Dr. Reddy’s Laboratories Ltd., Fresenius SE & Co. KGaA, Leap Labchem Co., LEO Pharma A/S, Sanofi S.A., Syntex S.A., Teva Pharmaceutical Industries Ltd., United Biotech (P) Ltd, Amphastar Pharmaceuticals Inc., Abbott Laboratories, Aspen Pharmacare Holdings, Laboratorios Farmaceuticos ROVI SA, and Intrapharm Laboratories.

Global Europe Heparin Market: Key Developments

Major players in the market are focused on adopting collaboration and partnership strategies to expand their product portfolio. For instance, in April 2018, Laboratorios Farmaceúticos Rovi SA signed a license expanding agreement with Hikma Pharmaceuticals PLC for ROVI’s enoxaparin biosimilar.

Heparin is obtained naturally from mucosal tissues of slaughtered meat animals such as porcine intestines or bovine lungs or prepared synthetically. It is also known as unfractionated heparin (UFH) and is used as an anticoagulant for treating acute coronary syndrome, atrial fibrillation (AF), venous thromboembolism (VTE), etc. Increasing prevalence of atrial fibrillation in developed and developing economies along with increasing research and development activities is anticipated to drive the market growth during the forecast period. Moreover, major players in the market are also focused on assessing the efficacy of heparin alternatives in the treatment which in turn is also expected to assist the market growth.

Key features of the study:

  • This report provides in-depth analysis of the Europe Heparin market  and provides market size (US$ million) and compound annual growth rate (CAGR %) for the forecast period (2020–2027), considering 2019 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends,  regional outlook, and competitive strategy adopted by key players
  • It profiles key players in the Europe Heparin market  based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
  • Key companies covered as a part of this study include, Pfizer, Inc., Sagent Pharmaceuticals, Inc., B. Braun Melsungen AG, Baxter International Inc., GlaxoSmithKline plc, Bayer AG, Anselm Pharmaceuticals, Bristol-Myers Squibb Co., Dr. Reddy’s Laboratories Ltd., Fresenius SE & Co. KGaA, Leap Labchem Co., Sanofi S.A., Syntex S.A., LEO Pharma A/S, Teva Pharmaceutical Industries Ltd., United Biotech (P) Ltd, Amphastar Pharmaceuticals Inc., Abbott Laboratories, Aspen Pharmacare Holdings, Laboratorios Farmaceuticos ROVI SA, and Intrapharm Laboratories.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, technology up-gradation, market expansion, and marketing tactics
  • The Europe Heparin market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the Europe Heparin market

Detailed Segmentation:

  • Europe Heparin Market, By Product Type:
    • Low Molecular Weight Heparin
    • Unfractionated Heparin
    • Ultra Low Molecular Weight Heparin
  • Europe Heparin Market, By End User:
    • Hospitals
    • Blood and Stem Cell Bank
    • Others (Laboratories, Acute Care Centers)
  • Europe Heparin Market, By Region:
    • North America
      • By Product Type:
        • Low Molecular Weight Heparin
        • Unfractionated Heparin
        • Ultra Low Molecular Weight Heparin
      • By End User
        • Hospitals
        • Blood and Stem Cell Bank
        • Others (Laboratories, Acute Care Centers)
      • By Country
        • U.S.
        • Canada
    • Latin America
      • By Product Type:
        • Low Molecular Weight Heparin
        • Unfractionated Heparin
        • Ultra Low Molecular Weight Heparin
      • By End User
        • Hospitals
        • Blood and Stem Cell Bank
        • Others (Laboratories, Acute Care Centers)
      • By Country
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Product Type:
        • Low Molecular Weight Heparin
        • Unfractionated Heparin
        • Ultra Low Molecular Weight Heparin
      • By End User
        • Hospitals
        • Blood and Stem Cell Bank
        • Others (Laboratories, Acute Care Centers)
      • By Country
        • U.K.
        • Germany
        • France
        • Spain
        • Italy
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Product Type:
        • Low Molecular Weight Heparin
        • Unfractionated Heparin
        • Ultra Low Molecular Weight Heparin
      • By End User
        • Hospitals
        • Blood and Stem Cell Bank
        • Others (Laboratories, Acute Care Centers)
      • By Country
        • China
        • Japan
        • India
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • By Product Type:
        • Low Molecular Weight Heparin
        • Unfractionated Heparin
        • Ultra Low Molecular Weight Heparin
      • By End User
        • Hospitals
        • Blood and Stem Cell Bank
        • Others (Laboratories, Acute Care Centers)
      • By Country
        • GCC Countries
        • Israel
        • Rest of Middle East
    • Africa
      • By Product Type:
        • Low Molecular Weight Heparin
        • Unfractionated Heparin
        • Ultra Low Molecular Weight Heparin
      • By End User
        • Hospitals
        • Blood and Stem Cell Bank
        • Others (Laboratories, Acute Care Centers)
      • By Country
        • North Africa
        • Central Africa
        • South Africa
  • Company Profiles
    • Pfizer, Inc. *
      • Company Overview
      • Product Portfolio
      • Key Highlights
      • Financial Overview
      • Strategies
    • Sagent Pharmaceuticals, Inc.
    • B. Braun Melsungen AG
    • Baxter International Inc.
    • GlaxoSmithKline plc
    • Bayer AG
    • Anselm Pharmaceuticals
    • Bristol-Myers Squibb Co.
    • Dr. Reddy’s Laboratories Ltd.
    • Fresenius SE & Co. KGaA
    • Leap Labchem Co.
    • LEO Pharma A/S
    • Sanofi S.A.
    • Syntex S.A.
    • Teva Pharmaceutical Industries Ltd.
    • United Biotech (P) Ltd
    • Amphastar Pharmaceuticals Inc.
    • Abbott Laboratories
    • Aspen Pharmacare Holdings
    • Laboratorios Farmaceuticos ROVI SA
    • Intrapharm Laboratories
  •  “*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objectives and Assumptions
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Purview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Product Type
      • Market Snippet, By End User
      • Market Snippet, By Country
      • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • Impact Analysis
    • Key Highlights
    • Product launch
    • PEST Analysis
    • Technological Advancements
    • Regulatory Scenario
    • Mergers and Acquisitions
    • Impact of COVID19 on the market
  4. Europe Heparin Market, By Product Type, 2019 – 2027, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • Low Molecular Weight Heparin
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Unfractionated Heparin
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Ultra Low Molecular Weight Heparin
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
  5. Europe Heparin Market, By End User, 2019 – 2027, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • Hospitals
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Blood and Stem Cell Bank
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Others (Laboratories, Acute Care Centers)
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
  6. Europe Heparin Market, By Region, 2019 – 2027, (US$ Mn)
    • Introduction
      • Market Share Analysis, By Region, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, For Regions, 2017–2026
    • North America
      • Market Size and Forecast, By Product Type, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By End User, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
        • U.S.
        • Canada
    • Latin America
      • Market Size and Forecast, By Product Type, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By End User, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • Market Size and Forecast, By Product Type, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By End User, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
        • Germany
        • U.K.
        • France
        • Spain
        • Italy
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Market Size and Forecast, By Product Type, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By End User, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
        • China
        • Japan
        • India
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • Market Size and Forecast, By Product Type, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By End User, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
        • GCC Countries
        • Israel
        • Rest of Middle East
    • Africa
      • Market Size and Forecast, By Product Type, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By End User, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
        • North Africa
        • Central Africa
        • South Africa
  7. Competitive Landscape
    • Company Profiles
      • Pfizer, Inc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Sagent Pharmaceuticals, Inc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • B. Braun Melsungen AG
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Baxter International Inc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • GlaxoSmithKline plc
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Bayer AG
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Anselm Pharmaceuticals
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Bristol-Myers Squibb Co.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Dr. Reddy’s Laboratories Ltd.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Fresenius SE & Co. KGaA
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Leap Labchem Co.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • LEO Pharma A/S
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Sanofi S.A.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Syntex S.A.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Teva Pharmaceutical Industries Ltd.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • United Biotech (P) Ltd
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Amphastar Pharmaceuticals Inc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Abbott Laboratories
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Aspen Pharmacare Holdings
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Laboratorios Farmaceuticos ROVI SA
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Intrapharm Laboratories
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
  8. Section
    • References
    • Research Methodology
    • About us and Sales Contact

*Browse 22 market data tables and 14 figures on “Heparin Market - Europe forecast to 2027”.

Frequently Asked Questions

The Europe Heparin market size was valued at US$ 2,698.7 million in 2019 and is estimated to exhibit a CAGR of 6.1% between 2020 and 2027.
France is anticipated to grow at a higher rate of CAGR during the forecast period owing to an increasing prevalence of cardio vascular diseases.
Major factor driving the growth of Europe Heparin market during the forecast period Increasing prevalence of venous thromboembolism, and adoption of expansion strategies from major companies.
Major factors hampering the growth of the Europe Heparin market during the forecast period constitutes of availability of alternative anticoagulants.
Germany market is expected to generate the highest revenue during the forecast period.
Some of the key players operating in the market are Pfizer, Inc., Sagent Pharmaceuticals, Inc., B. Braun Melsungen AG, Baxter International Inc., GlaxoSmithKline plc, Bayer AG, Anselm Pharmaceuticals, Bristol-Myers Squibb Co., Dr. Reddy’s Laboratories Ltd., Fresenius SE & Co. KGaA, Leap Labchem Co., Sanofi S.A., Syntex S.A., LEO Pharma A/S, Teva Pharmaceutical Industries Ltd., United Biotech (P) Ltd, Amphastar Pharmaceuticals Inc., Abbott Laboratories, Aspen Pharmacare Holdings, Laboratorios Farmaceuticos ROVI SA, and Intrapharm Laboratories.
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner